Stock RIGL RIGEL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665597024

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-10 pm EDT 		5-day change 1st Jan Change
8.59 USD +5.53% Intraday chart for Rigel Pharmaceuticals, Inc. +11.13% -40.76%
Jun. 25 Rigel Pharmaceuticals to Implement 1-for-10 Reverse Stock Split MT
Jun. 25 Sector Update: Health Care Stocks Advance Pre-Bell Tuesday MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Rigel Pharmaceuticals : Leonteq Securities AG ISIN Änderung (Sponsored Segment)
Rigel Pharmaceuticals to Implement 1-for-10 Reverse Stock Split
Sector Update: Health Care Stocks Advance Pre-Bell Tuesday
Rigel Pharmaceuticals Completes Transfer of Gavreto New Drug Application
Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application
Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Rigel Pharmaceuticals Seeks Acquisitions
Rigel Pharmaceuticals Enters Collaboration to Study Possible Treatment for Brain Tumors; Shares Rise
Rigel Pharmaceuticals, Inc. Announces Collaboration with Connect to Conduct a Phase 2 Trial of Olutasidenib in Glioma
Rigel Pharmaceuticals, MD Anderson Partner for Research on New Rezlidhia Indications
Rigel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center Announce Strategic Alliance to Advance REZLIDHIA®? (Olutasidenib) in AML and Other Cancers
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition
Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RIGL Stock
  4. News Rigel Pharmaceuticals, Inc.
  5. Other languages